Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022
On April 6, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the National Kidney Foundation Spring Clinical Meetings 2022 in Boston, scheduled for April 6-10, 2022. The company will present three significant posters focusing on real-world healthcare costs, adherence to phosphate binders, and thrombotic events in dialysis-dependent patients. Notably, Vadadustat, an investigational drug for chronic kidney disease anemia, received a complete response letter from the FDA on March 29, 2022, while still under review by the European Medicines Agency.
- Participation in a high-profile medical conference may enhance visibility.
- Presentation of multiple research posters highlights ongoing research efforts.
- Vadadustat's complete response letter from the FDA raises questions about its approval timeline.
- Pending regulatory review may impact market perception and investor confidence.
CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022 (SCM22), which will take place on demand and live in Boston on April 6 – 10, 2022.
Abstracts are available online in the SCM22 Abstract and ePoster Gallery: https://cme.kidney.org/spa/courses/resource/2022-spring-clinical-meetings/event/home/posters/browser
Akebia posters include:
- Real-World All-Cause Healthcare Costs Among Dialysis-Dependent Patients with Chronic Kidney Disease on Phosphate Binders (Poster #189)
- Real-World Adherence and Persistence on Phosphate Binders Among Dialysis-Dependent Patients with Chronic Kidney Disease (Poster #190)
- Hemodialysis Access Thrombotic Events in Patients with Dialysis-Dependent CKD Randomized to Vadadustat vs. Darbepoetin Alfa (Poster #280)
NKF SCM22 attendees can visit the Akebia booth (#915) or virtual booth in NKF's 2022 Spring Clinical Meeting Virtual Exhibit Hall: https://cme.kidney.org/spa/courses/resource/2022-spring-clinical-meetings/event/home/expo.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational new drug and is not approved by the U.S. Food and Drug Administration (FDA). On March 29, 2022, the FDA issued a complete response letter to Akebia's New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is currently under review by the European Medicines Agency for the treatment of anemia due to CKD in adults. In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-poster-presentations-at-national-kidney-foundation-spring-clinical-meetings-2022-301518572.html
SOURCE Akebia Therapeutics
FAQ
What event is Akebia Therapeutics participating in April 2022?
What drug did Akebia receive a complete response letter for?
Where can I find more information about Akebia's poster presentations?
What is Vadadustat used for?
Is Vadadustat approved in any regions?
